oncnursingnews4h
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...
oncnursingnews8h
Telephone Follow-Ups May Reduce AEs in Locally Advanced ESCC
Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...
oncnursingnews2d
Bevacizumab’s Benefit in Colorectal Cancer May Be Limited to 2 Years Post-Administration
The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...
oncnursingnews3d
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
oncnursingnews3d
22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers
Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...
oncnursingnews2d
Aspirin Linked to Lower CRC Recurrence in Patients With PI3K Mutations
Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...
oncnursingnews7d
Topical Gel Demonstrates Significant Efficacy in EGFR Inhibitor-Induced Skin Toxicity
Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...
oncnursingnews3d
Tislelizumab Plus Chemotherapy Demonstrates Strong Anti-Tumor Activity in ESCC
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...
oncnursingnews10d
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...